LAPIX Therapeutics Announces Positive Topline Phase 1 Clinical Data Results with LPX-TI641 for the Treatment of Autoimmune ...
LPX-TI641 is an oral novel Treg-expanding T cell/transmembrane, immunoglobulin, and mucin (Tim)receptor agonist therapy in development for the treatment of autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and multiple sclerosis with …